X
[{"orgOrder":0,"company":"Affiris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFFiRiS: Positive Phase 1 Results with Immunotherapies Targeting PCSK9 to Treat Hypercholesterolemia Published Peer Reviewed Journal","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Affiris"},{"orgOrder":0,"company":"Affiris","sponsor":"Frontier Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AFFiRiS and Frontier Biotechnologies Announce License Agreement for AFFITOPE\u00aeAT04, an Active Immunotherapy Targeting PCSK9 to Treat Hypercholesterolemia, in Greater China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Affiris"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Subject to the terms of the agreement, Frontier Biotechnologies will be responsible for all development costs for AFFITOPE® AT04 occurring in Greater China and will receive the rights to develop, manufacture and exclusively commercialize AT04 in the licensed territory.
Lead Product(s):
Affitope AT04,Aluminium Oxyhydroxide
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Affitope AT04
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Frontier Biotechnologies
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
December 22, 2021
Details:
AFFITOPE® peptide vaccine candidates AT04A and AT06A are safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune response in the cardiovascular disease indication hypercholesterolemia.
Lead Product(s):
AT04A
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: AT04A
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 27, 2021